Neurolief
Neurolief is a private medical technology company that developed ProlivRx, the first FDA-approved at-home brain neuromodulation system for adults with major depressive disorder who have failed antidepressant medication, selling it via authorized prescribers, health systems, and the Veterans Affairs healthcare network.
- Company typePrivate
- Founded2013
- HeadquartersNetanya, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Neurolief does
Neurolief Inc. is a private medical technology company developing non-invasive brain neuromodulation therapies for neurological and psychiatric disorders, with its lead and only commercial product, ProlivRx, focused on major depressive disorder (MDD) in adults who have failed to achieve adequate improvement on at least one antidepressant medication. The company's core technology is external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS), a focal, multi-channel neuromodulation method that delivers gentle electrical pulses through an external headset-style device to targeted occipital and trigeminal afferent neural pathways. ProlivRx was granted FDA Premarket Approval in December 2025 as the first and only prescription brain neuromodulation system authorized for at-home use in this indication, supported by clinical outcomes of 87% improvement in depression severity and 96% adherence across a structured 8-16 week treatment program with continuous physician oversight.
Neurolief generates revenue through prescription sales of the ProlivRx system, distributed exclusively via authorized prescribers, health systems, behavioral health programs, and (as of 2026) the Veterans Affairs Federal Supply Schedule. Its commercial model is enterprise field sales targeting psychiatrists, health systems, and VA VISNs, with multi-year contract pricing and a physician enrollment workflow rather than direct-to-consumer distribution. Reported cost-economics claims — $35,000 estimated annual cost avoidance per patient based on actuarial analysis of reduced escalation to in-clinic neuromodulation, ER visits, and inpatient utilization — are positioned for payer and health system buyers rather than as company revenue figures.
The company is strategically anchored by BrainsWay Ltd., which has invested a total of $11 million through a $5M August 2025 tranche and a $6M March 2026 milestone-based convertible loan, and which holds a call option to acquire all outstanding equity in Neurolief subject to performance milestones. Neurolief is led by CEO Scott F. Drees, with co-founder Amit Dar as CTO, and operates across Netanya, Israel and Coral Springs, Florida with 11-50 employees.
Neurolief firmographics
Firmographics- Name
- Neurolief
- Legal name
- Neurolief Inc.
- Website
- https://neurolief.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Neurolief is a private medical technology company that developed ProlivRx, the first FDA-approved at-home brain neuromodulation system for adults with major depressive disorder who have failed antidepressant medication, selling it via authorized prescribers, health systems, and the Veterans Affairs healthcare network.
- Ownership category
- akta.pro rank
Neurolief industry classification
Industry- Product category
- Neuromodulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Offices of Physicians, Mental Health Specialists (621112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)
Keywords
Where Neurolief is headquartered
LocationHeadquarters
- HQ city
- Netanya
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
Neurolief business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- ProlivRx System Sales: Revenue generated from the sale of the FDA-approved ProlivRx neuromodulation system for at-home treatment of major depressive disorder, targeting health systems, VA healthcare facilities, and authorized prescribers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Prescription therapy program |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
Neurolief product offering
Product offeringCore offering
Neurolief develops and sells the ProlivRx (Proliv™Rx) system, an FDA-approved prescription brain neuromodulation device intended for adjunctive at-home treatment of Major Depressive Disorder in adults who have not achieved adequate improvement from at least one antidepressant medication. The device delivers focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) through gentle electrical pulses to targeted neural pathways and is operated under a structured 8–16 week physician-directed treatment program.
Product overview
Neurolief offers a single unified product: the Proliv™Rx system. This is an FDA-approved, physician-directed, at-home brain neuromodulation therapy designed as an adjunctive treatment for adults with major depressive disorder who have failed to achieve satisfactory improvement from at least one previous antidepressant medication. The system combines an at-home treatment experience with continuous physician direction and visibility throughout the program, delivered as a structured 8-16 week treatment program.
Differentiator
Problem solved
Functional benefit
Brands
- Proliv®Rx: FDA-approved at-home brain neuromodulation system for treatment-resistant Major Depressive Disorder. Provides focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) treatment.
Products and services
- ProlivRx (Proliv™Rx) Brain Neuromodulation System FDA-approved prescription brain neuromodulation system intended as an adjunctive treatment for Major Depressive Disorder (MDD) in adults who failed to achieve satisfactory improvement from at least one previous antidepressant medication. Delivers focal, multi-channel external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) via gentle electrical pulses to targeted neural pathways, for use at home or in clinic under physician direction. Structured 8–16 week treatment program with continuous adherence and symptom tracking.
Quantifiable outcome
- 87% of patients demonstrated improvement in depression severity after 16-week therapy program
- +3 more outcomes
Companies that use Neurolief
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Neurolief technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Neurolief partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- BrainsWay Ltd.coreStrategic investment partnership established as Neurolief prepared for FDA approval and commercial launch of ProlivRx. BrainsWay's expertise and global reach with its Deep TMS system are expected to help scale product deployment. The partnership includes plans for further funding contingent on revenue targets and options for acquisition as Neurolief scales commercial operations in the U.S.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Neurolief competitors and assessment
Company assessmentDirect peers
- BrainsWay: BrainsWay develops Deep Transcranial Magnetic Stimulation (Deep TMS) systems for major depressive disorder and other psychiatric conditions. It is the most direct competitor in non-invasive brain neuromodulation for MDD and also holds an $11M strategic investment and call option to acquire Neurolief, making it both competitor and potential acquirer.
- Neuronetics: Neuronetics markets the NeuroStar TMS system, the most widely used transcranial magnetic stimulation therapy for treatment-resistant major depressive disorder in the US. It directly competes with Neurolief in the TRD neuromodulation segment, though NeuroStar requires clinic-based delivery while ProlivRx is at-home.
- Flow Neuroscience: Flow Neuroscience offers a transcranial direct current stimulation (tDCS) headset for at-home treatment of depression, with regulatory approval in the EU and UK. It is a direct competitor in the at-home, prescription-style neuromodulation category for MDD that Neurolief occupies.
- Sooma Medical: Sooma develops transcranial direct current stimulation (tDCS) devices for depression and other neurological conditions, with CE marking for home-use treatment of major depressive disorder. It competes in the same at-home neuromodulation segment for MDD as Neurolief's ProlivRx system.
- Magstim: Magstim manufactures transcranial magnetic stimulation systems widely used in clinical research and depression treatment. Its TMS platforms compete with Neurolief's neuromodulation approach in the TRD treatment pathway, though delivered in clinical settings rather than at home.
- MagVenture: MagVenture develops and supplies transcranial magnetic stimulation systems used in depression treatment protocols across research and clinical settings. It competes in the broader non-invasive brain stimulation category for major depressive disorder that Neurolief addresses with ProlivRx.
- Neurosoft: Neurosoft manufactures repetitive transcranial magnetic stimulation (rTMS) systems for clinical use in psychiatric and neurological conditions, including depression. It operates in the same non-invasive brain stimulation treatment space for MDD as Neurolief.
Emerging players
- Apollo Neuroscience: Apollo Neuroscience develops wearable low-frequency stimulation devices designed for consumer and wellness use cases including stress, sleep, and focus. It is an emerging player in at-home neuromodulation with adjacent use cases to Neurolief's clinical MDD therapy, though positioned in the wellness category rather than prescription treatment.
- COMPASS Pathways: COMPASS Pathways is developing psilocybin therapy for treatment-resistant depression, with FDA Breakthrough Therapy designation. It is an emerging participant in the TRD treatment landscape and represents a potential alternative non-pharmacological intervention pathway alongside Neurolief's neuromodulation approach.
Broad incumbents
- Sage Therapeutics: Sage Therapeutics developed zuranolone (Zurzuvae), an FDA-approved oral therapy for postpartum depression and an investigated treatment for MDD, in partnership with Biogen. As a larger biopharmaceutical incumbent, it competes with Neurolief in the broader MDD treatment landscape, though through pharmacology rather than neuromodulation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Neurolief social profiles
Digital presenceNeurolief compliance and trust
Trust signalCompliance1 record
Neurolief financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neurolief leadership team
Management profileNumber of profiles
Profiles4 records
Neurolief funding detail
Funding detailFunding overview
Funding rounds7 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neurolief M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neurolief
What does Neurolief do?
Neurolief develops and sells the ProlivRx (Proliv™Rx) system, an FDA-approved prescription brain neuromodulation device intended for adjunctive at-home treatment of Major Depressive Disorder in adults who have not achieved adequate improvement from at least one antidepressant medication. The device delivers focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) through gentle electrical pulses to targeted neural pathways and is operated under a structured 8–16 week physician-directed treatment program.
Is Neurolief a public or private company?
Neurolief is a private company. It is classified as venture growth investor backed and is currently operating.
When was Neurolief founded?
Neurolief was founded in 2013. It employs 11 to 50 people.
Where is Neurolief based?
Neurolief is headquartered in Netanya, Israel, in the Middle East region.
How does Neurolief make money?
One revenue line is on record: prolivRx System Sales.
Who are Neurolief's main competitors?
Direct peers on record are BrainsWay, Neuronetics, Flow Neuroscience, Sooma Medical, Magstim, MagVenture and Neurosoft. Emerging players are Apollo Neuroscience and COMPASS Pathways. Sage Therapeutics is listed as a broad incumbent.
Does Neurolief have an API?
No public API is recorded for Neurolief.
What industry is Neurolief in?
Neurolief's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 334510 and its SIC code is 3845.